Abstract
There are numerous lines of evidence pointing to norepinephrine being of crucial importance in pathophysiology of anxiety and mood disorders. First, norepinephrine projections innervate the limbic system, suggesting the involvement of norepinephrine in the regulation of emotions and cognition. Second, norepinephrine closely interacts with serotonin and dopamine systems, which also play very important roles in the regulation of mood. Third, it has been shown that various agents which increase norepinephrine availability, such as norepinephrine reuptake inhibitors, are also effective antidepressant drugs. And fourth, the depletion of norepinephrine causes a resurgence of depressive symptoms after successful treatment with noradrenergic antidepressant drugs. These observations suggest that the intensification of norepinephrine transmission can be beneficial in the treatment of affective disorders. However, various psychotropic medications have indirect effect on norepinephrine transmission. This review examines the effects of psychiatric medications on the norepinephrine system and proposes how they might be used to improve treatment outcome.
Current Drug Targets
Title: Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Volume: 10 Issue: 11
Author(s): Eliyahu Dremencov, Mostafa el Mansari and Pierre Blier
Affiliation:
Abstract: There are numerous lines of evidence pointing to norepinephrine being of crucial importance in pathophysiology of anxiety and mood disorders. First, norepinephrine projections innervate the limbic system, suggesting the involvement of norepinephrine in the regulation of emotions and cognition. Second, norepinephrine closely interacts with serotonin and dopamine systems, which also play very important roles in the regulation of mood. Third, it has been shown that various agents which increase norepinephrine availability, such as norepinephrine reuptake inhibitors, are also effective antidepressant drugs. And fourth, the depletion of norepinephrine causes a resurgence of depressive symptoms after successful treatment with noradrenergic antidepressant drugs. These observations suggest that the intensification of norepinephrine transmission can be beneficial in the treatment of affective disorders. However, various psychotropic medications have indirect effect on norepinephrine transmission. This review examines the effects of psychiatric medications on the norepinephrine system and proposes how they might be used to improve treatment outcome.
Export Options
About this article
Cite this article as:
Dremencov Eliyahu, Mansari el Mostafa and Blier Pierre, Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications, Current Drug Targets 2009; 10 (11) . https://dx.doi.org/10.2174/138945009789735165
DOI https://dx.doi.org/10.2174/138945009789735165 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Current Drug Abuse Reviews Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Nociceptinergic System as Potential Target in Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design The Neurophysiology of Hydrogen Sulfide
Inflammation & Allergy - Drug Targets (Discontinued) Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Highlighting the Protective or Degenerative Role of AMPK Activators in Dementia Experimental Models
CNS & Neurological Disorders - Drug Targets Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Postoperative Delirium
Current Drug Targets Sulfur Dioxide: a Novel Gaseous Signal in the Regulation of Cardiovascular Functions
Mini-Reviews in Medicinal Chemistry Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study
Central Nervous System Agents in Medicinal Chemistry Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Intracellular Signaling and Approaches to the Treatment of Schizophrenia and Associated Cognitive Impairment
Current Pharmaceutical Design Modulation of Dopamine Transmission by 5HT2C and 5HT3 Receptors: A Role in the Antidepressant Response
Current Drug Targets Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets